Russell Investments Group Ltd. Sells 16,752 Shares of Biohaven Ltd. (NYSE:BHVN)

Russell Investments Group Ltd. decreased its position in Biohaven Ltd. (NYSE:BHVN - Free Report) by 10.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 146,125 shares of the company's stock after selling 16,752 shares during the quarter. Russell Investments Group Ltd. owned about 0.14% of Biohaven worth $5,458,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in BHVN. Vanguard Group Inc. grew its stake in Biohaven by 8.1% in the 4th quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company's stock valued at $314,267,000 after buying an additional 628,211 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Biohaven by 144.5% in the fourth quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company's stock worth $73,922,000 after purchasing an additional 1,169,721 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Biohaven by 11.1% during the fourth quarter. Geode Capital Management LLC now owns 1,905,366 shares of the company's stock valued at $71,182,000 after acquiring an additional 190,754 shares during the period. ARS Investment Partners LLC grew its holdings in shares of Biohaven by 1.0% in the 4th quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company's stock worth $38,871,000 after purchasing an additional 10,473 shares during the last quarter. Finally, Norges Bank bought a new position in Biohaven during the 4th quarter valued at about $33,711,000. Institutional investors and hedge funds own 88.78% of the company's stock.

Biohaven Price Performance

Shares of Biohaven stock traded up $1.73 during trading on Friday, hitting $20.41. 2,098,008 shares of the company were exchanged, compared to its average volume of 1,110,098. The firm has a market capitalization of $2.08 billion, a P/E ratio of -2.18 and a beta of 1.33. The firm's fifty day moving average price is $28.43 and its 200 day moving average price is $38.58. Biohaven Ltd. has a 1-year low of $15.79 and a 1-year high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). As a group, equities research analysts anticipate that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Insiders Place Their Bets

In other Biohaven news, Director John W. Childs acquired 32,700 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the acquisition, the director now directly owns 2,320,571 shares of the company's stock, valued at approximately $70,707,798.37. This trade represents a 1.43 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 16.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft set a $60.00 target price on shares of Biohaven and gave the company a "buy" rating in a research note on Thursday, March 20th. Morgan Stanley reduced their price objective on Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a research note on Friday, March 7th. JPMorgan Chase & Co. decreased their target price on Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Finally, HC Wainwright reissued a "buy" rating and set a $54.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Biohaven currently has a consensus rating of "Buy" and a consensus target price of $62.77.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.